These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29507054)

  • 41. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
    Bates DJ; Salerni BL; Lowrey CH; Eastman A
    Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
    Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
    Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
    Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
    Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
    Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R; Morchon E; Martinez-Argudo I; Serrano R
    Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
    Du J; Widlund HR; Horstmann MA; Ramaswamy S; Ross K; Huber WE; Nishimura EK; Golub TR; Fisher DE
    Cancer Cell; 2004 Dec; 6(6):565-76. PubMed ID: 15607961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
    J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
    Wessely A; Steeb T; Berking C; Heppt MV
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.
    Vido MJ; Aplin AE
    J Invest Dermatol; 2015 Oct; 135(10):2355-2357. PubMed ID: 26358385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
    Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
    Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
    Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
    Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
    Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
    Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
    Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
    Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
    Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
    Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Garraway LA; Widlund HR; Rubin MA; Getz G; Berger AJ; Ramaswamy S; Beroukhim R; Milner DA; Granter SR; Du J; Lee C; Wagner SN; Li C; Golub TR; Rimm DL; Meyerson ML; Fisher DE; Sellers WR
    Nature; 2005 Jul; 436(7047):117-22. PubMed ID: 16001072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.